1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
September 24, 1996
Date of Report
(Date of earliest event reported)
GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-23736 52-1841960
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
6611 TRIBUTARY STREET
BALTIMORE, MARYLAND
(Address of principal executive offices)
21224
(Zip Code)
(410) 631-6300
(Registrant's telephone number, including area code)
2
ITEM 5. OTHER EVENTS
In connection with the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, Guilford Pharmaceuticals Inc.
("Guilford" or the "Company") is hereby filing cautionary statements
identifying important factors that could cause Guilford's actual results to
differ materially from those projected in forward-looking statements made by or
on behalf of Guilford.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(99) Additional Exhibits
99.1 Cautionary Statements for Purposes of the "Safe
Harbor" Provisions of the Private Securities
Litigation Reform Act of 1995.
- 2 -
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
GUILFORD PHARMACEUTICALS INC.
Date: September 24, 1996 By: /s/ Andrew R. Jordan
---------------------------------------
Andrew R. Jordan
Vice President, Chief Financial Officer
and Treasurer
- 3 -